About
Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing CAR T-cell therapies aimed at treating B cell-driven autoimmune diseases such as stiff person syndrome, multiple sclerosis, myasthenia gravis, systemic sclerosis, and lupus nephritis.
Explore Kyverna Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.